Clover Health's CFO Peter Kuipers to Present at 2025 Citi Global Healthcare Conference

Clover Health's CFO will present at the Citi Global Healthcare Conference on December 4, 2025. Webcast available online.

Quiver AI Summary

Clover Health Investments, Corp. announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on December 4, 2025, at 11:15 a.m. Eastern Time, with a live webcast available on the company's investor relations website. Clover Health is a technology company focused on improving access to healthcare for Medicare recipients, particularly seniors. Their approach utilizes the Clover Assistant software platform to aggregate patient data, enhance clinical decision-making, and improve health outcomes by managing chronic diseases. Clover provides Medicare Advantage plans and extends its technology services to healthcare providers nationwide through its subsidiary, Counterpart Health. The company has documented the positive impacts of its technology on various health conditions and aims to reduce healthcare costs while improving patient outcomes.

Potential Positives

Clover Health's CFO, Peter Kuipers, will present at a significant industry conference, which enhances visibility and investor interest in the company.
The company is committed to improving healthcare access for Medicare patients, with a focus on underserved populations, which highlights its social responsibility and market potential.
Clover Health's innovative software platform, Clover Assistant, is designed to improve health outcomes and reduce costs, showcasing their technological advancement in the healthcare sector.
The positive impact of Clover's technology on chronic disease management is supported by published data, indicating the effectiveness of their solutions in enhancing patient care.

Potential Negatives

Announcement of the CFO's presentation may imply a lack of confidence in current financial performance, necessitating public engagement to reassure investors.
The focus on highlighting technology and healthcare access may draw attention to any shortcomings in patient outcomes or product performance not addressed in the release.
The ongoing emphasis on technology and data utilization raises concerns about potential regulatory scrutiny or compliance issues in the healthcare space.

FAQ

What date will Clover Health present at the Citi Global Healthcare Conference?

Clover Health will present on Thursday, December 4, 2025, at 11:15 a.m. Eastern Time.

Where can I access the live webcast of Clover Health's presentation?

The live webcast and replay can be accessed on Clover Health's investor relations website at https://investors.cloverhealth.com/.

Who is Clover Health's Chief Financial Officer?

The Chief Financial Officer of Clover Health is Peter Kuipers.

What is Clover Health's main focus?

Clover Health is focused on providing access to affordable, high-quality healthcare for seniors on Medicare.

What technology does Clover Health use to improve healthcare outcomes?

Clover Health uses the Clover Assistant software platform to support clinical decision-making and improve health outcomes.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CLOV Insider Trading Activity

$CLOV insiders have traded $CLOV stock on the open market 14 times in the past 6 months. Of those trades, 4 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:

VIVEK GARIPALLI has made 2 purchases buying 446,980 shares for an estimated $998,996 and 0 sales.
CONRAD WAI (CEO, Counterpart Health) has made 0 purchases and 2 sales selling 209,797 shares for an estimated $692,968.
JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 8 sales selling 102,899 shares for an estimated $308,712.
ANNA U LOENGARD has made 2 purchases buying 26,500 shares for an estimated $68,755 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CLOV Hedge Fund Activity

We have seen 89 institutional investors add shares of $CLOV stock to their portfolio, and 132 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BANK OF AMERICA CORP /DE/ removed 3,879,613 shares (-96.7%) from their portfolio in Q3 2025, for an estimated $11,871,615
MARSHALL WACE, LLP removed 3,523,047 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,780,523
RENAISSANCE TECHNOLOGIES LLC removed 2,780,900 shares (-26.5%) from their portfolio in Q3 2025, for an estimated $8,509,554
DIVISADERO STREET CAPITAL MANAGEMENT, LP added 2,768,088 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,470,349
CITADEL ADVISORS LLC removed 2,042,721 shares (-57.9%) from their portfolio in Q3 2025, for an estimated $6,250,726
QUBE RESEARCH & TECHNOLOGIES LTD removed 1,746,937 shares (-82.6%) from their portfolio in Q3 2025, for an estimated $5,345,627
GOLDMAN SACHS GROUP INC removed 1,494,774 shares (-63.3%) from their portfolio in Q3 2025, for an estimated $4,574,008

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CLOV Analyst Ratings

Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 11/06/2025

To track analyst ratings and price targets for $CLOV, check out Quiver Quantitative's $CLOV forecast page.

$CLOV Price Targets

Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $3.35.

Here are some recent targets:

Richard Close from Canaccord Genuity set a target price of $3.7 on 11/06/2025
Jonathan Yong from UBS set a target price of $3.0 on 08/06/2025

Full Release

WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. Eastern Time.

A live webcast and replay of the presentation will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/ .

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence , Congestive Heart Failure , Chronic Obstructive Pulmonary Disease , and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease .

Investor Relations:
Ryan Schmidt
[email protected]

Press Inquiries:
[email protected]